SloveniaThe FDA has approved Moderna’s flu vaccine, mFLUSIVA (mRNA-1010), for use in individuals aged 50 and older, despite a contentious approval process. The independent advisory committee had previously recommended approval, but the FDA delayed its decision until August 5th. Initially, the FDA rejected the application, later reconsidered, and faced challenges due to the Health Secretary’s opposition and changes to the advisory board composition. While the approval marks progress, broader implementation remains uncertain. The CDC and its Advisory Committee on Immunization Practices (ACIP) have yet to endorse the vaccine, as the committee has been blocked by disputes over member qualifications. Additionally, federal vaccination promotion programs face pressure and potential shutdowns, which could delay widespread adoption. Although Moderna has prepared the vaccine for this flu season, large-scale usage is expected only in the 2027/28 winter.
Bias read (Center): The article presents a balanced account of the political and bureaucratic hurdles surrounding the vaccine approval, including the FDA’s internal deliberations, the Health Secretary’s stance, and the challenges facing the CDC and ACIP. It does not overtly favor any particular political ideology or sl
